Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hamburg Edoxaban for Anticoagulation in COVID-19 Study

NCT04542408 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT04542408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04542408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 3
Overall status
Completed
Start date
November 12, 2020
Completion date
January 15, 2023
Enrollment
140 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid19